43° National congress of the italian society of pharmacology creating value through pharmacological research
Evento RES di 3P Solution Srl · 25 - 28 novembre 2026 · Torino
Congresso nazionale SIF (Società Italiana di Farmacologia), 4 giorni a Torino, con sessioni ECM in farmacologia sperimentale, traslazionale e clinica: metabolismo, dolore cronico, neuroscienze, malattie infiammatorie, epilessie e farmacologia di genere.
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.
Razionale scientifico
A congress of a learned society serves to showcase the activities and research of the members, to imagine and shape together the future of the discipline, and to bring together professionals with similar backgrounds to allow them to establish collaborations and exchange best practices. The Congress in Turin embraces all three of these missions. Ample space will be given, as usual, to high-quality research. Yet, there are important changes compared to the past. The traditional oral communications have been converted into topic symposia organized exclusively by the early-career pharmacology members. Furthermore, an effort has been made, whenever possible, to bring together basic and clinical content. Indeed, while a good researcher in any discipline is measured by the ability to answer relevant scientific questions and thus push the boundaries of knowledge, a pharmacologist has a further challenge: to move transversally across all areas of drug development, from target identification to market access dynamics, encompassing preclinical, non-clinical and clinical research, evidence generation and evaluation, as well as regulation and market dynamics. The congress aims to be a showcase of the golden age we are experiencing. Drugs are being developed much more rapidly than in the past, a significantly greater number of drugs is being developed, and the available technologies have increased substantially. This new wealth is accompanied by increased complexity at every level and therefore by the need for significant changes. Proximity of care, system sustainability, telemedicine, translational medicine, precision medicine, prevention, and artificial intelligence are no longer slogans but are embedded in the pharmaceutical world we live in. In this context, the role of the pharmacologist is central, as the transversal nature of the profession will bring significant value to the system. Finally, the congress will address many of the key cross-cutting themes at the heart of current discussions, from high-quality basic research to new tools in clinical research, from real-world evidence to regulatory uncertainties, from evidence-based medicine to the personalization of therapies, including gender pharmacology, and from economic sustainability to organizational innovation. The congress will bring together leading experts from academia, the public and private sectors, thereby fostering a high-level and productive scientific environment. To support this process, structured networking opportunities will be provided for trainees, members serving on Ethics Committees, professionals working in Phase I Units and molecular tumor boards, and members of the SIF sections.
Luogo
Centro Congressi Lingotti
Via Nizza, 280, Torino (TO)
Programma
25 November 2026· Meeting Room Roma, Centro Congressi Lingotto, Torino
- 13:30–15:30SY24 Pharmacological innovations for the management of metabolic disorders and their comorbidities
- 13:30Targeting the liver-brain axis in diabesity-associated Alzheimer's disease: hepatic NLRP3 as a pharmacological nodeClaudio Pirozzi
- 13:45Impact of ANGPTL3-targeted therapies on lipids and apolipoproteins: a meta-analysis of randomized controlled trialsElena Olmastroni
- 14:00Beyond the trip: the metabolic action of psilocybin in steatotic liver diseaseAnna Signor
- 14:15Competing risk of death and neurological outcomes in elderly diabetic patients treated with GLP-1 receptor agonistsVera Battini
- 14:30Effects of N-acylethanolamines on obesity-induced cardiometabolic alterationsFederica Comella
- 14:45Pharmacological modulation of the paracannabinoid system in diet-induced overweight: insights into early cardiac dysfunctionAlessia Campagna
- 15:00Cholinergic stimulation promotes resilience and PD-L1 expression in human terminally differentiated β-cells: implications for novel Type 1 Diabetes strategiesFrancesco Petragnano
- 15:15Adolescent high-fat diet programs a lipotoxic and bioenergetically inefficient skeletal muscle phenotype: protective role of oleoylethanolamideChristian Sepe
26 November 2026· Meeting Room Roma, Centro Congressi Lingotto, Torino
- 8:30–10:00SY01 From visceral to somatic pain: mechanisms, pathways, and therapeutic targets
- 8:30μ-opioid receptor in NK cells as a potential biomarker for neuropathic pain: evidence from the CCI model and modulation by bergamot polyphenolic fractionLucia Carmela Passacatini
- 8:45Decoding vulvodynia: from pelvic sensitivity to central pain processingMichela Perrone
- 9:00Exploring the dual role of Mangifera indica L. in alleviating abdominal visceral pain and inflammationAnna Schettino
- 9:15Dissecting the gut–vulva axis: translational insights from IBS-associated vulvodynia and evaluation of glucosinolates-based therapyElena Lucarini
- 9:30From intestinal epithelium to visceral pain: molecular mechanisms involved in IBSSofia Faggin
- 9:45Dissecting MOR-CB1 interactions in neuronal cell models: implications for opioid-cannabinoid co-treatment in chronic painGaia Lusoli
- 10:00–11:30S5 Vulnerability to relapse: behavioral, circuit and molecular fingerprints
- 10:00Cocaine withdrawal during adolescence alters hippocampal neuro-glia interaction dynamics and excitatory–inhibitory synapses in response to an acute stressLucia Caffino
- 10:20Impact of adolescent social exclusion on relapse susceptibility to alcohol seeking and stress-related behaviors in male and female ratsEsi Domi
- 10:40Dorsal raphe projections to the central amygdala and nucleus accumbens drive methamphetamine relapseDaniele Caprioli
- 11:00Multidimensional addiction profiling in outbred rats: from individual differences to medication developmentGiordano de Guglielmo
- 11:30–12:30S24 Modelling and simulation as drivers of innovation in pharmacology
- 11:30From data to modelOscar Della Pasqua
- 11:45From mechanistic knowledge to translational impact: a systems biology and QSP perspectiveEnrico Domenici
- 12:00Regulatory impact of PK and PD modelling and simulation: expectations and practical casesSerena Zamponi
- 12:15Novel approaches to HypoparathyroidismMaria Luisa Brandi
- 14:30–16:00S18 Optimizing polypharmacy management in complex patients: key priorities, tools, and strategic approaches
- 14:30Medication reviews and pharmacogenetics: the critical role of data integrationValeria Conti
- 14:45Medication review in different care settings, constraints and potential benefitsElisabetta Poluzzi
- 15:00Artificial Intelligence in medication review and deprescribing servicesGianluca Trifirò
- 15:15Clinical assessment of drug–drug interactions: insights from a national pilot studyRiccardo Giossi
- 15:30AIFA's Position Paper on the implementation of precision medicineRobert Nisticò
- 16:00–17:30S1 Chronic pain 2.0: emerging mechanisms and therapeutic strategies
- 16:00Emerging strategies for pain management in Fabry Disease, a rare genetic disorderSilvia Franchi
- 16:15Proteome-wide characterization of neuroinflammatory signatures in morphine-exposed spinal tissue: modulation by ultramicronized palmitoylethanolamideAlessandra Toti
- 16:30Effect of conditioned diet in a model of early life-induced widespread pain: potential role of HCAR2 receptorsCarmela Belardo
- 16:45Neuroinflammatory mechanisms in opioid-related side effectsLaura Rullo
- 17:00NanoBEO: transdermal nanotechnology for the management of pain and agitation in severe dementiaDamiana Scuteri
27 November 2026· Meeting Room Roma, Centro Congressi Lingotto, Torino
- 8:30–9:30SY25 Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions
- 8:30Dysfunctional gut microbiota–endocannabinoid axis exacerbates skeletal muscle and brain deficits in Duchenne muscular dystrophy (DMD)Noemi Di Muraglia
- 8:45Sex-dependent modulation of audiogenic seizures by ketogenic diet in a GluN2A(N615S) model of GRIN-related encephalopathyAlessandra Lodi
- 9:00Sex-specific lipid mediator profile drives pulmonary fibrosis pathogenesis in miceDanilo D'Avino
- 9:15Sex-specific pharmacotherapy and vascular stiffness in hypertensionMarialuisa Sveva Marozzi
- 9:30–11:00S14 Psychedelics and more: innovative treatments for neurodevelopmental diseases and therapeutic challenges
- 9:30Sex dependent behavioral and brain molecular effects of psilocybin in mice exposed to early life stressLaura Musazzi
- 9:50Psilocybin in neurodevelopmental disorders: preclinical insights into mechanisms of actionViviana Trezza
- 10:10Cortico-striatal pathophysiology for neurodevelopmental disorders associated with 16p11.2 CNVs: implications for therapeutic targetingIlaria Maria Morella
- 10:30SHANK3 related autism: from cell biology to new treatment opportunitiesChiara Verpelli
- 11:00–12:30S33 From maternal well-being to offspring mental health: molecular determinants of intergenerational vulnerability
- 11:00Mechanistic insights into how gestational stress programs long-term vulnerabilityAlessia Marchesin
- 11:15Examine the association between maternal cannabis use and sex-specific dysfunctional mitochondrial bioenergetics leading to dopamine-related psychopathological traits in the offspringFederico Brandalise
- 11:30Maternal depression and psychosocial stress, before and during pregnancy, alter neurodevelopmental trajectories of the progeny by remodeling placental transcriptional and epigenetic landscapesJuliet Richetto
- 11:45Demonstrate how post-parturition alcohol exposure disrupts neuroadaptations driven by motherhoodSebastiano Bariselli
- 12:00Deciphering the role of IL-17A in ASD-like phenotypes: evidence from a maternal immune activation mouse modelAnna Maria Tartaglione
- 12:15Sex-divergent effects of cannabidivarin treatment in rats prenatally exposed to VPAErica Zamberletti
- 14:30–16:00S27 Therapeutic advances in developmental and epileptic encephalopathies: present and future
- 14:30From genotype-phenotype correlations to emerging therapeutic strategies in SCN1A-related neurological disordersPaola Imbrici
- 14:50Gut Microbiota in Angelman Syndrome: toward biomarkers and novel therapeutic strategiesCarmen De Caro
- 15:10Investigating sex differences in a validated model of GRIN2A-related DEE: psychopathological and therapeutic implicationsIlaria Bertocchi
- 15:20Targeted therapies in KCNQ2-related developmental and epileptic encephalopathiesFrancesco Miceli
28 November 2026· Meeting Room Roma, Centro Congressi Lingotto, Torino
- 8:30–10:00SY27 Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms
- 8:30RACK1 modulation as a mechanistic platform for screening immunotoxic effects of endocrine disrupting chemicalsMirco Masi
- 8:45Environmental chemicals as drivers of neuronal vulnerability: glutamatergic receptor dynamics in critical developmental windowsMelania Maria Serafini
- 9:00Nanoplastic co-exposure as an emerging environmental driver of metabolic dysfunction in liver and adipose tissueStefania Melini
- 9:15Downregulation of Kv7 channels contributes to angiotensin-II induced modulation of neuronal activity in brain areas controlling sympathetic toneStefania Iervolino
- 9:30Invisible invaders: subacute nanoplastic ingestion drives neuroinflammation via the gut-brain axisFederico Ciceri
- 9:45Early life stress alters hypothalamic-peripheral metabolic signaling linking psychiatric and metabolic vulnerabilityIlari D'Aprile
- 10:00–11:30S16 Biological therapies and molecular target drugs in chronic inflammatory autoimmune diseases: from basic and translational research to clinical evidence
- 10:00A new frontier in IL-17 antagonism: FM15TM, a first-in-class linear small peptide with translational potential in chronic inflammation and autoimmune diseasesFrancesco Maione
- 10:20Reframing IMIDs: the IL-23 pathway from mechanisms to pharmacological perspectivesLuca Antonioli
- 10:40Novel imaging-based methods for validating immunopharmacology in vivoIshii Masaru
- 11:00Autoimmune diseases from a pharmacological perspective: mechanisms and clinical challengesAnnamaria Iagnocco
Responsabili del corso
3P SOLUTION SRL
Provider
ID Provider: N° 327
Città: Milano (MI)
Tipologia: Società, Agenzie Ed Enti Privati
Stato accreditamento: Standard - 2° Rinnovo
Armando Genazzani
Responsabile scientifico
Specializzazione: Professore Universitario. Presidente Sif
Relatori e docenti
Stefania Maria Ceruti
Moderatore
Elena Olmastroni
Relatore
Claudio Pirozzi
Relatore
Con il contributo non vincolante di
- BAYER AG
- BLUEPRINT
- DOMPÉ FARMACEUTICI S.P.A.
- EISAI SRL
Domande frequenti
L'evento è accreditato per: Medico Chirurgo (Allergologia Ed Immunologia Clinica, Dermatologia E Venereologia, Medicina Fisica E Riabilitazione, Medicina Aeronautica E Spaziale, Psichiatria, Medicina Legale, Igiene, Epidemiologia E Sanità Pubblica, Medicina Dello Sport, Oftalmologia, Farmacologia E Tossicologia Clinica, Medicina Nucleare, Continuità Assistenziale); Chimico (Chimica); Medico Chirurgo (Gastroenterologia, Geriatria, Nefrologia, Neuropsichiatria Infantile, Chirurgia Maxillo-Facciale, Chirurgia Pediatrica, Neuroradiologia); Farmacista (Farmacista Pubblico Del Ssn); Medico Chirurgo (Direzione Medica Di Presidio Ospedaliero, Organizzazione Dei Servizi Sanitari Di Base, Medicina Subacquea E Iperbarica, Medicina Termale, Oncologia, Pediatria, Chirurgia Vascolare, Ginecologia E Ostetricia, Otorinolaringoiatria, Neurofisiopatologia); Biologo (Biologo); Medico Chirurgo (Cure Palliative, Epidemiologia, Endocrinologia, Malattie Infettive, Microbiologia E Virologia, Igiene Degli Alimenti E Della Nutrizione, Audiologia E Foniatria); Tecnico Sanitario Laboratorio Biomedico (Iscritto Nell’Elenco Speciale Ad Esaurimento); Medico Chirurgo (Angiologia, Genetica Medica, Malattie Dell'apparato Respiratorio, Neurologia, Cardiochirurgia, Chirurgia Toracica, Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia), Pediatria (Pediatri Di Libera Scelta), Scienza Dell'alimentazione E Dietetica); Farmacista (Farmacista Di Altro Settore); Medico Chirurgo (Cardiologia, Medicina Interna, Neonatologia, Reumatologia, Chirurgia Generale, Neurochirurgia, Anestesia E Rianimazione, Biochimica Clinica, Laboratorio Di Genetica Medica, Medicina Trasfusionale, Radiodiagnostica, Medicina Generale (Medici Di Famiglia)); Farmacista (Farmacista Territoriale); Medico Chirurgo (Psicoterapia, Medicina Di Comunità E Delle Cure Primarie, Ematologia, Malattie Metaboliche E Diabetologia, Medicina D'emergenza-Urgenza, Radioterapia, Chirurgia Plastica E Ricostruttiva, Ortopedia E Traumatologia, Urologia, Anatomia Patologica, Medicina Del Lavoro E Sicurezza Degli Ambienti Di Lavoro); Assistente Sanitario (Assistente Sanitario); Tecnico Sanitario Laboratorio Biomedico (Tecnico Sanitario Laboratorio Biomedico).
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.